Form 4: Immunome Director Sells $1.3M in Pre-Planned Stock Sales

Immunome Inc. Director and 10% owner Philip Wagenheim sold a total of 65,000 shares of common stock for approximately $1.3 million across two pre-scheduled transactions in March 2026.

Summary

• Philip Wagenheim, a Director and 10% owner of Immunome Inc. (IMNM), reported sales of common stock.
• On March 20, 2026, Wagenheim sold 36,800 shares at a weighted average price of $20.47 per share, totaling approximately $753,300.
• On March 23, 2026, an additional 28,200 shares were sold at a weighted average price of $20.65 per share, totaling approximately $582,330.
• The total number of shares sold across both transactions was 65,000, with a combined value of approximately $1,335,630.
• Following these transactions, Wagenheim beneficially owns 341,147 shares of Immunome Inc. common stock.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating they were pre-scheduled.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event because the sales were conducted under a pre-arranged 10b5-1 plan, which mitigates the negative signal typically associated with insider selling, suggesting personal financial planning rather than a lack of confidence in the company's future.

Positives

• The transactions were executed under a Rule 10b5-1(c) plan, suggesting the sales were pre-scheduled and not necessarily indicative of new negative information or a sudden loss of confidence.

Negatives

• A significant sale of 65,000 shares by a Director and 10% owner could be perceived negatively by the market, potentially signaling a desire to diversify holdings or a belief that the stock has reached a favorable selling point.
• The total value of shares sold exceeded $1.3 million, representing a notable reduction in the insider's direct holdings.

Risks

• Potential for increased selling pressure on Immunome Inc. stock if the market interprets this large insider sale negatively, despite the 10b5-1 plan.
• Possible erosion of investor confidence if the market perceives the insider sale as a signal of future underperformance, even with the pre-arranged nature of the transactions.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The filing includes the signature of Sandra Stoneman, Attorney-in-Fact for Philip Wagenheim, dated March 23, 2026, but no direct management commentary on the company's operations or outlook.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common occurrence in the biotechnology and pharmaceutical sectors, where executives often diversify their holdings after vesting periods or significant stock appreciation. While not inherently negative, large sales by significant shareholders like a 10% owner can sometimes be scrutinized more closely by investors looking for signals about future company performance, especially in a volatile industry like biotech.

Comparison to Industry Standards

• StockSavvy.ai observes that insider sales under Rule 10b5-1 plans are a standard practice for executives and directors to manage their personal finances while avoiding accusations of trading on material non-public information.
• Similar pre-arranged sales are frequently seen at companies like Amgen or Gilead Sciences, where executives periodically sell shares as part of their long-term financial planning.
• The sale amount, while substantial for an individual, is not unusual for a 10% owner of a publicly traded biotech firm, particularly if the stock has seen recent appreciation.

Related Party Transactions

• The sale of common stock by Philip Wagenheim, a Director and 10% owner, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May scrutinize the sale, potentially leading to short-term selling pressure, though the 10b5-1 plan mitigates the perception of a negative signal.
• Employees: Unlikely to have a direct impact on employees, but could subtly affect morale if perceived as a lack of confidence by leadership.

Next Steps

• The reporting person will continue to be subject to Section 16 obligations for any future transactions.
• The company or SEC staff may request full information regarding the number of shares sold at each separate price within the reported ranges.

Key Dates

Recommendation

While a significant insider sale by a director and 10% owner might typically warrant caution, the execution under a Rule 10b5-1 plan suggests these were pre-scheduled transactions for personal financial management rather than a reaction to new negative information. Therefore, this event alone does not provide a strong enough signal to change an existing investment thesis, leading to a 'hold' recommendation for current investors.

Keywords

Immunome Inc., IMNM, Philip Wagenheim, insider trading, Form 4, stock sale, director, 10% owner, common stock, Rule 10b5-1, biotech, pharmaceutical